ACCESS Newswire

Re:NewCell AB (publ)

5.11.2021 08:31:39 CET | ACCESS Newswire | Press release

Share
Interim Report Q3 2021

STOCKHOLM, SE / ACCESSWIRE / November 05, 2021 / Re:NewCell AB (publ) (FRA:6QP) (STO:RENEW)

Establishment in Sundsvall according to plan - moving from preparations into construction and mounting of equipment

July - September

Financial information

  • Net sales for the period amounted to SEK 636 thousand (328).
  • The loss after financial items amounted to SEK -24,538 thousand (-15,877).
  • Cash flow from operating activities amounted to SEK -31,567 thousand (-13,529).
  • Cash flow from investing activities was SEK -131,039 thousand (-371).
  • Earnings per share, before and after dilution, amounted to SEK -0.8 (-0.8).
  • The net cash position equaled SEK 425,842 thousand (17,379).

Significant events during the interim period

  • On July 2, Renewcell received an approved environmental permit for the planned operations in Ortviken in Sundsvall. The permit is valid with immediate effect.
  • On September 3, the Extraordinary General Meeting approved the Board's proposal to establish a warrantbased incentive program for key personnel and to enter into a loan agreement with the European Investment Bank (EIB).

January-September

Financial information

  • Net sales for the period amounted to SEK 1,465 thousand (1,221).
  • The loss after financial items amounted to SEK -67,205 thousand (-47,651).
  • Cash flow from operating activities amounted to SEK -64,985 thousand (-38,903).
  • Cash flow from investing activities was SEK -218,934 thousand (-704).
  • Earnings per share, before and after dilution, amounted to SEK -2.1 (-2.5).

Significant events after the interim period

  • On October 12, Levi's® announced that it will launch a version of its iconic 501® jeans partially made with Circulose®.
  • On October 19, Renewcell signed a letter of intent with Kelheim Fibers GmbH on anual sales of up to 10 000 tonnes Circulose®.
  • During October, the Company received the first loan disbursements corresponding to approximately SEK 320 million.

CEO's comments

Establishment in Ortviken according to plan - moving from preparations into construction and mounting of equipment.
The work with the establishment in Ortviken has now entered a new phase, meaning that Renewcell's new operations in Ortviken is beginning to take physical shape. At the beginning of the quarter the old Paper machine 5 (PM5) removed and the machine hall mostly empty. Since then, we have carried out preparatory work as planned, such as demolition of unusable installations and later piling and casting of foundations for the machines to be installed. We are happy to conclude that Ortviken has once again proved to provide excellent conditions for the establishment of Renewcell's operations as problems with basic civil work often means costly delays for companies in new establishments. We have continued our investments in machinery, equipment and organization during the quarter. For the most part, we have been able to manage the general cost increases for building materials by changing to more cost-effective materials in places where appropriate. Despite the fact that costs have increased slightly, we are still in a good position in relation to our budget. The project has so far not been affected either by the supply shortage because our larger orders were placed before the disturbances struck with greater force during the summer and late summer. So far, the global imbalance in commodity flows have not affected us. Nevertheless, our major logistics flows will start around Q2 2022, so we will follow the development for container shipping prices carefully. All in all, we therefore still have so far seen no reason to change our financial planning.

The market's interest in Circulose® remains strong. After planned test runs and optimization work as well as a summer break at the facility in Kristinehamn, we got off to a strong start during the third quarter and are well in phase in relation to our goals regarding availability and quality. We continue to sell industrial quantities to customers for both commercial fiber production and testing.

In line with our "pull strategy" in the value chain, we have during the period worked intensively with both existing and new brand partners. With the relatively low supply of Circulose® at present, it is a matter of allocating existing volume to pilot collections and quality tests, and at the same time deepening conversations about how we can help brand partners achieve their stated goals of becoming sustainable during this decade.

World leaders will soon gather in Glasgow for the delayed COP26 climate summit. In the words of the IPCC, it is now code red humanity and the 1.5-degree target may soon be out of reach. Sustainability is probably the strongest macro trend right now, and which is even stronger than digitalisation. There are few heads of state or company leaders who do not put sustainability extremely high on the agenda. We are confident that humanity has the opportunity to solve the climate crisis. Renewcell's message is that the situation is serious, but that with boldness, innovation and hard work we can actually build a long-term sustainable world. Here, Renewcell is well positioned for many years of development to create a sustainable textile and fashion industry

Stockholm, November 2021
Patrik Lundström - CEO

Contacts

Patrik Lundström
CEO
patrik.lundstrom@renewcell.com
+46 76 183 47 17

Hugo Petit
CFO
hugo.petit@renewcell.com
+46 70 7787196

About Renewcell

Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) (‘Renewcell') is a multi-award-winning sustaintech company based in Sweden. The company's vision is to inspire an Industrial Evolution to a sustainable world by producing high quality materials from recycled textiles.

Through its patented process, Renewcell is able to upcycle cellulosic textile waste, such as cotton clothes, transforming it into a pristine new material called Circulose®. Fast Company named Renewcell one of the World's Most Innovative Companies 2021. Circulose® was also included on TIME Magazine's list of the 100 Best Inventions 2020.

Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Renewcell's Certified Adviser, +46(0)8-528 00 399, info@fnca.se .

This information is information that Re:NewCell AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-05 08:00 CET.

Attachments

Interim Report Q3 2021 Renewcell
Q3 Interim Report Renewcell Presentation 211105

SOURCE: Re:NewCell AB (publ)



View source version on accesswire.com:
https://www.accesswire.com/671345/Interim-Report-Q3-2021

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release

NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata

Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in

Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release

LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als

Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release

NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye